The trophism of brain-derived neurotrophic factor (BDNF) for dopaminergic cells in culture has led to signifint interest in the role of BDNF in the etiology and potential treatment of Parkinson disease. Previous in .vo investIgation of BDNF delivery to axotomized anta nira dopaminergic neurons in the adult rat has shown no protective effect. In this study, we produced nigral degeneration by insing l-methyl-4-phenylpyrldinlum (MPP+), a mitochondrial complex I inhibitor and the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), into the rat striatum. The subsequent loss of nigral neurons was presumably due to mitochondrial toxicity after MPP+ uptake and retrograde transport to the substantla nira. We engired immortalzed rat fibroblasts to secrete human BDNF and Implanted these cells near the substantia nigra 7 days before striatal MPP+ infusion. We found that BDNF-secreting fibroblasts markedly increased nI do ergic neuronal survival when compared to control fibroblast Implants. The observation that BDNF prevents MNPTP-induced dopaminergc neuronal degeneration in the adult brain has sgncance for the reatment of neurodegenerative disorders, whih may involve mitochondrial dysfunction, such as Parkinson disease.
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The range of neuroprotective effects for any putative neurotrophic molecule must be determined in in vivo models of neurodegeneration (1) (2) (3) (4) (5) (6) (7) (8) before practical application of neurotrophic factor neuroprotection can be contemplated (9) . Of particular interest are neurotrophic factors found to protect in vivo against neuronal death caused by mechanisms similar to those thought to occur in human neurodegenerative disorders, such as nerve growth factor (NGF) protection against Huntington disease-like lesions ofthe striatum (7, 8) or ciliary neurotrophic factor protection in a mouse model of motoneuron degeneration (10) . Brain-derived neurotrophic factor (BDNF) (11, 12) promotes the survival offetal mesencephalic dopaminergic cells in culture (13) . In vivo, BDNF protects cholinergic neurons from degeneration after fimbria-fornix lesions (4) and motoneurons from degeneration after axotomy (5, 6) ; however, BDNF does not rescue axotomized substantia nigra compacta (SNC) dopaminergic neurons after axotomy (4) .
However, the cellular insults that cause some human neurodegenerative diseases may be only partially modeled by axotomy-induced cell death (14) (15) (16) . Other insults to cellular integrity, such as impaired energy metabolism, may more accurately model the degeneration seen in Huntington disease or Parkinson disease (17) (18) (19) (20) . Indeed, evidence for abnormalities in mitochondrial function has been found in patients with both of these disorders (21, 22) . A well described animal model ofParkinson disease is produced by the systemic injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into mice or primates (23) . MPTP, which is metabolized to the mitochondrial complex I inhibitor 1-methyl4phenylpyridinium (MPP+), causes dopaminergic cell death in the SNC, presumably due to mitochondrial impairment (for review, see ref. 24) . BDNF has been shown to protect dopaminergic neurons against MPP+ toxicity in culture (13 Seed, Massachusetts General Hospital) as described (25) and as shown in Fig. 1A . Rat I BDNF subclones were selected under G418 and then screened for their level ofBDNF mRNA production by Northern blot analysis and for their level of BDNF secretion as determined by an in vitro rat dorsal root ganglion neurite outgrowth bioassay, as described (26, 27 cluded from cell counting analysis. TH-positive cell counts were averaged from three Rat I confluent plates as control and from seven Rat I-BDNF no. 7 confluent plates and are expressed as means ± SD. These two conditions were compared by t test to confirm the bioactivity of the secreted BDNF (Fig. 1C) .
Cell Preparation and Implantation Substantia Nigra Degeneration Model. Cells were harvested by trypsin treatment and injected as a suspension in PBS with CaCl2 (1.0 mg/ liter)/MgCl2 (1.0 mg/liter)/0.1% glucose. Cell count and viability were assessed by trypan blue dye exclusion before intracerebral injection into rat hosts. Rat I cells not altered by retroviral infection were injected into control animals. Under pentobarbital anesthesia (65 mg/kg), eight male SpragueDawley rats (300-350 g) were grafted with Rat I fibroblast cells (BDNF [-] ) and eight rats were grafted with Rat I-BDNF no. 7 cells (BDNF[+]). Using a Kopfrat stereotactic frame, burr holes for grafting into the dorsal tegmentum ofthe mesencephalon were made at coordinates calculated from bregma as AP -5.3, L -2.4. Injections were made using a 10-I4 Hamilton syringe at V -6.0 calculated from the dura.
A total of 2 x 105 cells were infused over 2 min in a vol of 2 pl; the needle was withdrawn after a 1-min pause. Seven days after cell implantation, animals received MPP+ infusions into the striatum (28) . In a manner identical to that described above, burr holes for injection were calculated from bregma and made at AP + 1.0, L -2. Morphometri Procedures. The maximal cross-sectional area of the striatal lesion, as seen by characteristic neuronal loss after cresyl violet staining, was determined for each animal and measured as described (7) . SNC neurons were visually counted bilaterally both on Nissl-stained sections and on TH-immunostained sections. Since all SNC cell counts are expressed as a percentage of surviving cells relative to the control cell number on the non-MPP+-injected side, no correction factors were used. The TH-immunopositive SNC cell counts were independently confirmed by two observers, one ofwhom was blinded to the treatment regime. RESULTS BDNF-Secreting Fibroblasts. Immortalized fibroblasts were engineered to secrete BDNF using techniques previously employed for constructing NGF-secreting fibroblasts (25) . As described (26) , transgenic BDNF mRNA synthesis was screened by Northern blotting of total RNA from Rat I BDNF cells followed by hybridization to a radiolabeled human preproBDNF antisense cRNA probe. This analysis revealed an mRNA species of similar size to previously described preproNGF-neoR (neomycin resistance) mRNA transcribed in the identical vector backbone (29) .
BDNF secretion by the engineered cells was initially screened by testing Rat I BDNF conditioned medium in a neurite outgrowth assay using neonatal rat dorsal root ganglion explants. The presence of BDNF secretion by the highest producing selected subclone was fully confirmed by coculture ofRat I-BDNF no. 7 cells with TH-immunopositive fetal ventral mesencephalic neurons (Fig. 1B) , a specific property of BDNF bioactivity, as described (13) .
Striatal Infusion of MOPP+ and SNC Degeneration. The presence of significant striatal lesions due to infusion of 100 nmol of MPP+ was confirmed in every animal by characteristic neuronal loss after cresyl violet staining (Fig. 2B) . The lesion size was quantifiable by selection and measurement of a maximal cross-sectional lesion area for each animal, as has been performed previously for excitotoxic lesions in the striatum (7, 8 Cell counting of Nissl-stained neurons within the lesioned (Fig. 2C) anld nonlesioned (Fig. 2D ) SNC of animals grafted with BDNF[-] cells showed a 53% decrease in neurons on the lesioned side, to 47% + 11% of the nonlesioned side, consistent with previous observations of SNC degeneration in this model (30) . There was a significantly greater reduction in TH-immunopositive cells than in Nissl-stained neurons (P < 0.017) in the SNC on the side of the striatal lesion in BDNF [-] implanted animals, to 35% ± 15% (Fig. 3) . Particularly noteworthy is a very high inverse correlation (R = 0.921; F = 27.957; P < 0.003) between striatal lesion crosssectional areas and percentage Nissl-stained SNC neurons on the side of the lesion in animals implanted with BDNF [-] grafts. This emphasizes the utility of this model for studying MPP+-mediated SNC degeneration. The correlation between striatal lesion sizes and TH-immunopositive SNC cells approached significance (R = 0.709; F = 5.053; P < 0.075).
Placement of BDNF[+] grafts near the SNC on the lesioned side resulted in a significant (P < 0.001) increase in the percentage of surviving Nissl-stained neurons to 86% ± 18% and rendered the correlation between striatal lesion size and SNC cell survival not significant (R = 0.394; F = 0.919; P = 0.382). The effect of the BDNF-secreting grafts on TH cell survival was also dramatic (P < 0.001) in that BDNF [+] grafts promoted the survival of 83% + 22% of the THimmunopositive SNC cells on the side of the lesion (Fig. 3B) . The magnitude of these changes is shown graphically in Fig.  3D plantation ofthese fibroblasts near the substantia nigra in rats 7 days before striatal infusion of MPP+ significantly protected against subsequent SNC TH-immunopositive neuronal death. Nissl-stained neurons were significantly spared in BDNF [+] animals when compared to BDNF [-] controls.
In addition to a local lesion, infusion of MPP+ into rat striatum causes a profound loss of dopaminergic SNC neurons (28, 30) . This is presumably due to the uptake of MPP+ by dopaminergic terminals in the striatum and retrograde transport to the SNC (31) . In the present study, the loss of substantia nigra neurons was highly correlated with striatal lesion size. This correlation between striatal lesion size and SNC cell loss implies a similar cause for both striatal and SNC neuronal death. Since other insults that cause massive striatal excitotoxic lesions, such as toxic levels of N-methyl-D-aspartate receptor agonists, do not cause appreciable SNC cell loss (32, 33) , the cause of the SNC degeneration would likely be direct MPP+ effects on SNC neurons, not an indirect effect from the striatal neuronal death. The neuronal death in the substantia nigra is likely caused by mitochondrial blockade after retrograde transport of MPP+ from striatum to SNC and therefore acutely models the dopaminergic cell loss seen in Parkinson disease. Interestingly, patients with Parkinson disease can manifest mitochondrial defects (22, 34) or, more specifically, a deficiency in mitochondrial complex I activity (35, 36) .
The protective effects of BDNF on survival of dopaminergic neurons in this model probably reflect a trophic influence on neuronal function, perhaps through increased mitochondrial efficiency or by induction of cellular protective mechanisms. Mechanisms of neurotrophin-mediated neuroprotection in the adult brain are poorly understood. NGF, the most extensively investigated neurotrophin, is known to modulate a number of intracellular events, including changes in intracellular Ca2+ stores (37) , Na+/K+-ATPase activity (38) , C1-flux (39) , and induction of the peroxidative enzyme catalase, both in culture (40) and in vivo (41) . BDNF protects cultured neuroblastoma cells against MPP+ and 6-hydroxydopamine toxicity and induces a 100% increase in the activity of glutathione reductase, a protective enzyme (42) . However, BDNF had no effect on catalase activity in that system. NGF and BDNF share significant homology (43); both are able to bind to a low-affinity neurotrophin receptor (44) , and both bind with high affinity to specific members of the trk family of receptors (45) (46) (47) . It seems possible that BDNF may also mediate intracellular changes similar to those described for NGF. There also exists a level of specificity in neuronal populations for neurotrophin activity; for example, NGF does not protect cultured dopaminergic neurons against MPP+ toxicity (13) . Basic fibroblast growth factor (bFGF), on the other hand, does have some protective effects against MPTP toxicity in the mouse (48) but does not share homology with BDNF. The suggestion has been made that bFGF may cause glial cells to secrete neurotrophic factors, which in turn affect neuronal protection (49) . These observations imply either multiple, complementary protective pathways for neurotrophic support or a final common pathway, which can be activated through a number of receptors.
In vivo, BDNF protects against cholinergic neuronal degeneration after fibria-fornix lesioning (4) 
